XNASCVAC
, Last price
3.70USD
Name
CureVac NV
Chart & Performance
P/E
—
P/S
14.94
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.65%
Rev. gr., 5y
33.10%
Revenues
54m
-20.26%
Net income
-260m
L+4.47%
CFO
-268m
L-6.39%
Earnings
May 21, 2025
Profile
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 53,758 -20.26% | 67,420 -34.54% | ||||
Cost of revenue | 316,523 | 335,954 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (262,765) | (268,534) | ||||
NOPBT Margin | ||||||
Operating Taxes | 198 | (126) | ||||
Tax Rate | ||||||
NOPAT | (262,963) | (268,408) | ||||
Net income | (260,167) 4.47% | (249,029) -39.51% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 236,086 | 66,484 | ||||
BB yield | ||||||
| Debt | ||||||
Debt current | 5,005 | 4,980 | ||||
Long-term debt | 78,643 | 79,192 | ||||
Deferred revenue | 48,100 | 72,549 | ||||
Other long-term liabilities | 61,339 | |||||
Net debt | (321,461) | (416,112) | ||||
| Cash flow | ||||||
Cash from operating activities | (267,887) | (286,177) | ||||
CAPEX | (52,320) | (93,222) | ||||
Cash from investing activities | (55,200) | (93,499) | ||||
Cash from financing activities | 230,893 | 63,173 | ||||
FCF | (299,886) | (309,717) | ||||
| Balance | ||||||
Cash | 405,113 | 500,284 | ||||
Long term investments | (4) | |||||
Excess cash | 402,421 | 496,913 | ||||
Stockholders' equity | 516,941 | 534,734 | ||||
Invested Capital | 204,444 | 210,780 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 220,833 | 189,075 | ||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (239,379) | (244,793) | ||||
EV/EBITDA | ||||||
Interest | 2,493 | 3,707 | ||||
Interest/NOPBT | ||||||